JO
CRNX icon

John Overdeck’s Crinetics Pharmaceuticals CRNX Stock Holding History

John Overdeck’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.27M Hold
87,299
– – ﹤0.01% 2550
2026
Q1 		$3.17M Buy
87,299
+37,600
+76% +$1.68M ﹤0.01% 2398
2025
Q4 		$2.31M Hold
49,699
– – ﹤0.01% 2325
2025
Q3 		$2.07M Sell
49,699
-3,080
-6% -$98.5K ﹤0.01% 2104
2025
Q2 		$1.52M Buy
+52,779
New +$1.63M ﹤0.01% 2008
2024
Q4 		– Sell
-5,414
Closed -$277K – 3250
2024
Q3 		$277K Sell
5,414
-5,386
-50% -$278K ﹤0.01% 2703
2024
Q2 		$484K Sell
10,800
-108,080
-91% -$4.99M ﹤0.01% 2390
2024
Q1 		$5.56M Sell
118,880
-74,221
-38% -$2.9M 0.01% 916
2023
Q4 		$6.87M Sell
193,101
-208,852
-52% -$6.4M 0.02% 836
2023
Q3 		$12M Buy
401,953
+310,418
+339% +$6.4M 0.03% 542
2023
Q2 		$1.65M Buy
91,535
+59,335
+184% +$1.18M ﹤0.01% 1590
2023
Q1 		$517K Buy
32,200
+7,588
+31% +$140K ﹤0.01% 2183
2022
Q4 		$450K Buy
24,612
+1,356
+6% +$23.9K ﹤0.01% 2065
2022
Q3 		$457K Sell
23,256
-23,489
-50% -$479K ﹤0.01% 1820
2022
Q2 		$872K Sell
46,745
-74,032
-61% -$1.48M ﹤0.01% 1603
2022
Q1 		$2.65M Sell
120,777
-16,515
-12% -$334K 0.01% 1207
2021
Q4 		$3.9M Sell
137,292
-9,000
-6% -$222K 0.01% 1351
2021
Q3 		$3.08M Buy
146,292
+29,982
+26% +$627K 0.01% 1589
2021
Q2 		$2.19M Buy
116,310
+58,366
+101% +$1.03M 0.01% 1778
2021
Q1 		$885K Buy
57,944
+4,033
+7% +$62.5K ﹤0.01% 2430
2020
Q4 		$761K Buy
53,911
+26,834
+99% +$374K ﹤0.01% 2202
2020
Q3 		$424K Sell
27,077
-26,735
-50% -$409K ﹤0.01% 2362
2020
Q2 		$943K Buy
+53,812
New +$917K ﹤0.01% 1573

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's CRNX Position: Q2 2026 in Review

John Overdeck held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 87,299 shares worth $3.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2550.

John Overdeck first reported a position in CRNX in Q2 2020 and has held it in 23 quarters since. The position peaked at $12M in Q3 2023. 264 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • John Overdeck held 87,299 shares of Crinetics Pharmaceuticals worth $3.27M as of Q2 2026.
  • John Overdeck left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2550 holding.
  • John Overdeck first reported a position in Crinetics Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • John Overdeck's Crinetics Pharmaceuticals position peaked at $12M in Q3 2023.
  • 264 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.